Want to see CGEM full AI Analyst Report?
Top Page
Cullinan Management
(NASDAQ:CGEM)
Select Model
Select Model
Rating:51Neutral
Price Target:
$17.50
▲(2.34% Upside)
Action:Reiterated
Date:08/06/26
Overall score is held back primarily by weak financial performance (no meaningful revenue, large losses, and significant cash burn with a declining equity base). Offsetting factors include a moderately positive technical trend (price above key moving averages with neutral momentum) and favorable recent clinical-stage pipeline updates, while valuation provides little support due to negative earnings and no dividend.
Positive Factors
Promising autoimmune pipeline data
Robust early Phase 1 efficacy and favorable safety for CLN-978 and velinotamig support a differentiated T‑cell engager franchise in autoimmune disease. Durable because positive disease‑modifying signals and outpatient subcutaneous dosing can translate into sustained clinical development value and future commercial opportunity if later trials confirm benefits.
Negative Factors
Large, persistent cash burn
Sustained multi‑year negative operating and free cash flow consumes capital and creates runway pressure. Intensifying burn relative to prior periods heightens the probability of dilutive financings or program slowdowns, constraining long‑term execution unless spending is reduced or new funding secured.
Read all positive and negative factors
Positive Factors
Negative Factors
Promising autoimmune pipeline data
Robust early Phase 1 efficacy and favorable safety for CLN-978 and velinotamig support a differentiated T‑cell engager franchise in autoimmune disease. Durable because positive disease‑modifying signals and outpatient subcutaneous dosing can translate into sustained clinical development value and future commercial opportunity if later trials confirm benefits.
Read all positive factors
Cullinan Management (CGEM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.01B
Dividend YieldN/A
Average Volume (3M)990.97K
Price to Earnings (P/E)―
Beta (1Y)0.96
Revenue GrowthN/A
EPS Growth-19.99%
CountryUS
Employees109
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.56
Shares Outstanding61,458,046
10 Day Avg. Volume530,726
30 Day Avg. Volume990,974
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)1.50
Price to Sales (P/S)0.00
P/FCF Ratio-3.48
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$33.67Price Target Upside96.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-3.04
Revenue Forecast (FY)$17.85M
Cullinan Management Business Overview & Revenue Model
Company Description
Cullinan Therapeutics, Inc. operates as a biopharmaceutical firm actively advancing its therapeutic candidates through clinical trials. This company is focused on developing innovative treatments primarily for cancer, including those that leverage...
Cullinan Management Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 18.94M |
| Gross Profit | -79.00K | 0.00 | -306.00K | -310.00K | 0.00 | 18.94M |
| EBITDA | -208.00M | -219.57M | -167.15M | -190.34M | -132.04M | -67.43M |
| Net Income | -204.69M | -219.88M | -167.38M | -153.16M | 111.21M | -65.57M |
Balance Sheet | ||||||
| Total Assets | 363.79M | 448.37M | 621.82M | 484.18M | 561.12M | 437.19M |
| Cash, Cash Equivalents and Short-Term Investments | 334.54M | 377.90M | 398.98M | 467.07M | 467.29M | 290.47M |
| Total Debt | 2.07M | 2.68M | 2.15M | 3.59M | 5.19M | 0.00 |
| Total Liabilities | 42.03M | 39.64M | 31.50M | 30.29M | 26.09M | 11.81M |
| Stockholders Equity | 321.75M | 408.73M | 590.33M | 453.70M | 535.03M | 424.97M |
Cash Flow | ||||||
| Free Cash Flow | -159.30M | -175.80M | -145.30M | -134.48M | -127.80M | -44.02M |
| Operating Cash Flow | -159.25M | -175.75M | -145.30M | -134.28M | -126.66M | -43.43M |
| Investing Cash Flow | 162.88M | 179.99M | -136.31M | 35.81M | 248.97M | -333.77M |
| Financing Cash Flow | 2.19M | 1.09M | 266.19M | 40.75M | -25.93M | 268.78M |
Cullinan Management Technical Analysis
Positive
17.10
Price Trends
16.53
Positive
15.38
Positive
13.24
Positive
Market Momentum
0.15
Positive
56.33
Neutral
85.45
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CGEM, the sentiment is Positive. The current price of 17.1 is below the 20-day moving average (MA) of 17.44, above the 50-day MA of 16.53, and above the 200-day MA of 13.24, indicating a bullish trend. The MACD of 0.15 indicates Positive momentum. The RSI at 56.33 is Neutral, neither overbought nor oversold. The STOCH value of 85.45 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CGEM.
Cullinan Management Risk Analysis
Cullinan Management disclosed 79 risk factors in its most recent earnings report. Cullinan Management reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cullinan Management Peers Comparison
UnderperformOutperform
Sector (51)
CGEM
Cullinan Management
17.95
10.92
155.33%
RNTX
Rein Therapeutics
0.79
-0.32
-29.01%
NEUP
Neuphoria Therapeutics
3.90
-3.85
-49.68%
Cullinan Management Corporate Events
Executive/Board ChangesShareholder Meetings
Cullinan Therapeutics Shareholders Back Directors and Governance Measures
Positive
Jun 16, 2026
Cullinan Therapeutics held its Annual Meeting of Stockholders on June 16, 2026, where investors voted on board composition, auditor retention and executive pay. Stockholders elected Nadim Ahmed and Stephen Webster as Class III directors to the boa...
Business Operations and StrategyProduct-Related Announcements
Cullinan Therapeutics Highlights Positive Early Autoimmune Trial Data
Positive
Jun 10, 2026
On June 10, 2026, Cullinan Therapeutics reported updated Phase 1 data from its OUTRACE trials of CLN-978 in treatment-refractory rheumatoid arthritis and moderate to severe systemic lupus erythematosus, showing robust efficacy in heavily pretreate...
Business Operations and Strategy
Cullinan Showcases Promising CLN-978 Phase 1 Autoimmune Data
Positive
Jun 8, 2026
On June 6, 2026, Cullinan Therapeutics presented initial Phase 1 data for CLN-978 in treatment-refractory systemic lupus erythematosus and rheumatoid arthritis at the EULAR Congress, based on 29 patients enrolled in the OUTRACE SLE and RA trials a...
Business Operations and StrategyProduct-Related Announcements
Cullinan Management Shares Promising Early CLN-978 Autoimmune Data
Positive
May 18, 2026
On May 18, 2026, Cullinan Therapeutics reported initial clinical data from two ongoing Phase 1 OUTRACE trials of CLN-978 in treatment-refractory rheumatoid arthritis and moderate to severe systemic lupus erythematosus. As of a January 14, 2026 cut...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.